focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Share News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: Whitbread Surges On Costa Coffee Sale

Fri, 31st Aug 2018 10:36

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Friday.----------FTSE 100 - WINNERS----------Whitbread, up 16%. The hospitality firm said it agreed the sale of its Costa Coffee business to US soft drinks giant Coca-Cola Co at an enterprise value of GBP3.90 billion. Whitbread, which also owns the Premier Inn hotel chain, is expecting net proceeds of GBP3.80 billion, and said most of this will be returned to shareholders. The sale, the company continued, will reduce debt and also allow for an increased pension contribution and further expansion of Premier Inn in both the UK and Germany. Whitbread believes a "substantial" premium would have been created by its planned demerger of Costa Coffee, which was announced in April this year. At the time the company had described itself as "committed" to demerging Costa after the coffee chain saw a decline in annual profit.----------FTSE 100 - LOSERS----------Sage Group, down 6.5%. The accounting software provider said Chief Executive Officer Stephen Kelly has stepped down from his role with immediate effect. He is to "remain available to the group" until May 31, 2019. Kelly has been chief executive of Sage for nearly four years since 2014. The FTSE 100 group has started the process to find a new chief executive. Chief Financial Officer Steve Hare has been given the additional post of chief operating officer on an interim basis, giving him full authority to run the business until a new chief executive is appointed. In addition, Sage said it has continued to trade in line with its full-year guidance of 7.0% organic revenue growth and a 27.5% organic operating margin. The group said achieving this guidance is dependent on the closing of several Enterprise Management opportunities in September.----------Evraz, down 1.5%, Glencore, down 1.2%, BHP Billiton, down 0.9%. The commodity stocks were lower amid concerns that the US-Chinese trade dispute may intensify and over metal tariffs. US President Donald Trump said he could move ahead with a plan to impose tariffs on USD200 billion in Chinese imports as early as next week. In addition, Trump also threatened to pull out from the World Trade Organization and called European trade policies "almost as bad as China," raising fresh worries over trade friction.----------FTSE 250 - WINNERS----------Hays, up 6.4%. Shares in the recruiter were rebounding after it expressed uncertainty for its UK market due to economic instability, despite reporting positive results for its recently ended financial year on Thursday. The stock closed down 4.7% on Thursday. ----------FTSE 250 - LOSERS----------Serco Group, down 3.1%. Exane BNP downgraded the outsourcer to Neutral from Outperform.----------OTHER MAIN MARKET AND AIM - WINNERS----------Midatech Pharma, up 31%. The rare disease-focused pharmaceutical company announced positive data from its proof of concept exploratory study for its key oncology drug candidate MTD201. MTD201 Q-Ocreotide is a sustained-release treatment for carcinoid cancer and acromegaly. In a a double-blind exploratory study, the tolerability, pharmacokinetics and growth hormone profiles after a 30 milligram injection in 24 healthy subjects were compared between MTD201 and Novartis AG's Sandostatin LAR. Results from the study indicated that MTD201 produces a safe sustained-release profile of octreotide with growth hormone levels suppressed by an average of 25%, comparable with Sandostatin. Midatech will now seek regulatory approval for MTD201 as an equivalent product of improved product to Sandostatin in preparation for a follow-on trial.----------OTHER MAIN MARKET AND AIM - LOSERS----------FFI Holdings, down 27%. The entertainment industry contract provider said profit halved as costs associated with its recently listing hurt despite revenue jumping on acquisitions. For the year ended March 31, pretax profit halved to USD5.3 million from USD10.3 million the year prior. This was despite revenue rising to USD58.9 million from USD38.8 million the year before. Profit performance was hurt by a sharp rise in administrative and exceptional costs. Administrative expenses rose to USD29.4 million from USD18.9 million the year prior primarily driven by a jump in staff costs. Exceptional costs also rose to USD10.7 million from USD1.9 million the year before which was chiefly related to USD9.5 million in initial public offering costs.----------
More News
24 Feb 2020 16:02

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
8 Jan 2020 15:51

Midatech shares surge on success of latest MTD201 study

(Sharecast News) - Biotechnology research and development company Midatech Pharma announced positive headline results from 'study 102' on Wednesday, which it said met its primary endpoints to confirm similar pharmacokinetics and bioavailability of octreotide for subcutaneous and intramuscular routes of administration.

Read more
8 Jan 2020 09:51

Positive Headline Reading For Latest Midatech MTD201 Study

Positive Headline Reading For Latest Midatech MTD201 Study

Read more
17 Dec 2019 16:39

Midatech Pharma American Shares Risk To Be Delisted Amid Low Bid Price

Midatech Pharma American Shares Risk To Be Delisted Amid Low Bid Price

Read more
5 Dec 2019 15:59

Midatech Pharma Gets EU Grant For Brain Cancer Drug

Midatech Pharma Gets EU Grant For Brain Cancer Drug

Read more
4 Nov 2019 18:47

Armistice Capital Takes Almost 10% Interest In Midatech Pharma

Armistice Capital Takes Almost 10% Interest In Midatech Pharma

Read more
24 Oct 2019 11:50

Midatech Pharma Childhood Cancer Drug Given FDA Orphan Designation

Midatech Pharma Childhood Cancer Drug Given FDA Orphan Designation

Read more
23 Oct 2019 09:29

Midatech Pharma Inks USD3.0 Million Registered Direct Offering Deal

Midatech Pharma Inks USD3.0 Million Registered Direct Offering Deal

Read more
8 Oct 2019 11:34

Midatech Doses First Patients In MTD201 Administration Method Study

Midatech Doses First Patients In MTD201 Administration Method Study

Read more
8 Oct 2019 09:24

Midatech Pharma doses first volunteers in acromegaly treatment study

(Sharecast News) - Midatech Pharma on Tuesday announced that its MTD201 Phase 1 study for the treatment of acromegaly and neuroendocrine tumours has commenced.

Read more
7 Oct 2019 15:45

DIRECTOR DEALINGS: Midatech Pharma CFO Buys GBP30,000 In Shares

DIRECTOR DEALINGS: Midatech Pharma CFO Buys GBP30,000 In Shares

Read more
3 Oct 2019 15:40

DIRECTOR DEALINGS: Midatech Pharma CFO Stephen Stamp Buys Shares

DIRECTOR DEALINGS: Midatech Pharma CFO Stephen Stamp Buys Shares

Read more
30 Sep 2019 19:06

Midatech Pharma Slims Interim Loss As Cancer Treatments Progress

Midatech Pharma Slims Interim Loss As Cancer Treatments Progress

Read more
24 Sep 2019 14:32

Midatech Pharma Applies To US Regulator For Share Issue Authority

Midatech Pharma Applies To US Regulator For Share Issue Authority

Read more
20 Sep 2019 15:43

Midatech Pharma gets approval for next MTD201 study

(Sharecast News) - Biotechnology company Midatech Pharma has received approval to commence a phase 1 study on MTD201, which it is developing for the treatment of acromegaly and neuroendocrine tumours (NET).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.